Staff Profile

Qualifications

BSc (Hons) Biomedical Science (Pharmacology), University of Aberdeen

PhD (Pharmacokinetics), Manchester University

Membership

International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)

British Pharmacological Society (BPS)

The British Association for Cancer Research (BACR)

Children’s Cancer and Leukaemia Group (CCLG)

I am currently a Lecturer in Cancer Pharmacology at Newcastle University within the Centre for Cancer. My main focus of research is in the area of paediatric clinical pharmacology. Primarily investigating the pharmacokinetics of chemotherapeutics used to treat challenging paediatric patient populations, such as neonates and infants.

Research Interests

• Paediatric Pharmacokinetics/ Clinical Pharmacology
• Therapeutic Drug Monitoring (TDM)
• Drug-Drug Interactions (DDIs)
• Endogenous biomarkers for DDI prediction
• Micro-sampling techniques

• Articles

  • Millen GC, Lawford A, Duncan C, Jenkinson H, Veal GJ, Barnett S. Utility of carboplatin therapeutic drug monitoring for the treatment of neonate and infant retinoblastoma patients in the United Kingdom. British Journal of Cancer 2024, 131, 491-497.
  • Mohmaed Ali MI, Nijstad AL, Boosman RJ, Crombag M-RBS, Barnett S, Veal GJ, Lalmohamed A, van Erp NP, Steeghs N, Zwaan CM, Beijnen JH, Siebinga H, Huitema ADR. A Population Pharmacokinetic Study to Evaluate Doxorubicin Exposure Across All Age Groups. Clinical Pharmacokinetics 2024, 63, 1711-1722.
  • Damoiseaux D, Amant F, Beijnen JH, Barnett S, Veal GJ, Huitema ADR, Dorlo TPC. Physiologically-based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk. CPT: Pharmacometrics and Systems Pharmacology 2023, 12(12), 1931-1944.
  • Barnett S, Makin G, Tweddle DA, Osborne C, Veal GJ. Generation of evidence-based carboplatin dosing guidelines for neonates and infants. British Journal of Cancer 2023, 129, 1773–1779.
  • Barnett S, Nyein AC, Galler M, Jamieson D, Davies M, Connor P, Veal GJ. Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report. Cancer Chemotherapy and Pharmacology 2023, 92, 325–328.
  • Barnett S, Hellman F, Parke E, Makin G, Tweddle DA, Osborne C, Hempel G, Veal GJ. Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients. European Journal of Cancer 2022, 164, 127-136.
  • Carruthers V, Barnett S, Rees R, Arif T, Slater O, Ramanujachar R, Johnson K, Brown S, Graham C, Burke GAA, Veal GJ. Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series. Pediatric Blood and Cancer 2022, 69(7), e29722.
  • Nijstad AL, Chu W-Y, de Vos-Kerkhof E, Enters-Weijnen CF, van de Velde ME, Kaspers GJL, Barnett S, Veal GJ, Lalmohamed A, Zwaan CM, Huitema ADR. A population pharmacokinetic modelling approach to unravel the complex pharmacokinetics of vincristine in children. Pharmaceutical Research 2022, 39, 2487-2495.
  • Barnett S, Errington J, Sludden J, Jamieson D, Poinsignon V, Paci A, Veal GJ. Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population. Pharmaceuticals 2021, 14(3), 272.
  • Takita H, Barnett S, Zhang Y, Ménochet M, Shen H, Ogungbenro K, Galetin A. PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability. CPT: Pharmacometrics & Systems Pharmacology 2021, 10(2), 137-147.
  • Barnett S, Ogungbenro K, Menochet K, Shen H, Humphreys GW, Galetin A. Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I. Journal of Pharmacology and Experimental Therapeutics 2019, 368(1), 125-135.
  • Barnett S, Ogungbenro K, Ménochet K, Shen H, Lai Y, Humphreys WG, Galetin A. Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation. Clinical Pharmacology & Therapeutics 2018, 104(3), 564-574.
  • Beedie SL, Rore HM, Barnett S, Chau CH, Luo W, Greig NH, Figg WD, Vargesson N. In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. Oncotarget 2016, 7(22), 33237-33245.
  • Beedie SL, Peer CJ, Pisle S, Gardner ER, Mahony C, Barnett S, Ambrozak A, Gütschow M, Chau CH, Vargesson N, Figg WD. Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. Molecular Cancer Therapeutics 2015, 14(10), 2228-2237.

• Letter

  • Geurten C, Errington J, Barnett S, Patel H, Noor S, Saraff V, Veal GJ, Gatz SA. Spontaneous fractures during 13-cis retinoic acid therapy for neuroblastoma. Pediatric Blood and Cancer 2023, 70(9), e30430.

• Reviews

  • Berezowska M, Hayden IS, Brandon AM, Zats A, Patel M, Barnett S, Ogungbenro K, Veal GJ, Taylor A, Suthar J. Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice. British Journal of Clinical Pharmacology 2025, 91(4), 1064-1079.
  • Barnett S, Holden V, Campbell-Hewson Q, Veal GJ. Perspectives and expertise in establishing a therapeutic drug monitoring programme for challenging childhood cancer patient populations. Frontiers in Oncology 2022, 11, 815040.
  • Nijstad AL, Barnett S, Lalmohamed A, Bérénos IM, Parke E, Carruthers V, Tweddle DA, Kong J, Zwaan CM, Huitema ADR, Veal GJ. Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance. European Journal of Cancer 2022, 164, 137-154.
  • Barnett S, Kong J, Makin G, Veal GJ. Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom. British Journal of Clinical Pharmacology 2021, 87(2), 256-262.